Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated Radiotherapy for Locally Advanced Cervical Cancer in Uganda
NCT07276360Phase 2Recruiting
- Sponsor
- Uganda Cancer Institute
- Start
- Mar 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Cervical Cancer (CC) (2 arms), sponsored by Uganda Cancer Institute. Primary endpoints: Incidence of adverse events at 90 days, Incidence of grade 3 or greater radiotherapy-related gastrointestinal or genitourinary AEs at 2 years and 1 more. Started Mar 2026; status: recruiting.
02
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT07276360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07276360.